Trial reportFrontiers in cardiovascular medicine2026
Early detection value of miR-29a in patients with acute myocardial infarction.
Trial report in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early detection of myocardial remodeling, a critical precursor to heart failure in acute myocardial infarction (AMI), remains inadequate with current biomarkers. Preclinical studies suggest miR-29a plays a role in these processes, yet its diagnostic value in early AMI remains unclear. This study evaluates the diagnostic and prognostic potential of miR-29a as a marker for myocardial remodeling in AMI patients. Methods: A prospective cohort study enrolled 52 patients with ST-elevation myocardial infarction (STEMI) caused by anterior descending branch occlusion, who underwent primary percutaneous coronary intervention within 12 h of symptom onset, along with 39 healthy controls. Results: Serum miR-29a levels were significantly elevated in STEMI patients compared to controls, exhibiting a graded increase with higher SYNTAX scores. MiR-29a levels positively correlated with soluble suppression of tumorigenicity 2 (sST2), N-terminal pro-brain natriuretic peptide (NT-proBNP), and the Tei index, while showing an inverse correlation with left ventricular ejection fraction (LVEF). Receiver operating characteristic (ROC) analysis indicated that serum miR-29a holds promise as a novel biomarker for early detection of myocardial remodeling in AMI. Furthermore, the combination of miR-29a with NT-proBNP and/or sST2 significantly enhanced diagnostic accuracy compared to individual biomarkers. The triad of miR-29a, NT-proBNP, and sST2 achieved the highest area under the curve (AUC) of 0.904, with 97.4% specificity and 76.9% sensitivity. Conclusion: Serum miR-29a shows significant potential as a biomarker for the early detection of myocardial remodeling in AMI, providing valuable diagnostic and prognostic insights.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.